




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61L 27/02, 31/02	A1	(11) International Publication Number: WO 00/66190 (43) International Publication Date: 9 November 2000 (09.11.00)
(21) International Application Number: PCT/GB00/01450 (22) International Filing Date: 27 April 2000 (27.04.00) (30) Priority Data: 9909996.2 1 May 1999 (01.05.99) GB 0005707.5 10 March 2000 (10.03.00) GB (71) Applicant (for all designated States except US): THE SECRETARY OF STATE FOR DEFENCE [GB/GB]; Defence Evaluation Research Agency, A4 Building, Ively Road, Farnborough, Hampshire GU14 0LX (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): CANHAM, Leigh, Trevor [GB/GB]; DERA Malvern, St. Andrews Road, Malvern WR14 3PS (GB). BARRETT, Christopher, Paul [GB/GB]; DERA Malvern, St. Andrews Road, Malvern, Worcestershire WR14 3PS (GB). (74) Agent: BOWDERY, A., O.; D/IPD, DERA Formalities, A4 Building, Ively Road, Farnborough, Hampshire GU14 0LX (GB).		(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>

(54) Title: DERIVATIZED POROUS SILICON



(57) Abstract

Biomaterial comprising derivatized porous silicon is described. Derivatization of the porous silicon has been found to increase its stability. The porous silicon is preferably derivatized by a technique that does not involve oxidation of the silicon, e.g. by hydrosilylation. The derivatized porous silicon is stable to boiling in aerated water for preferably at least two hours. The derivatized porous silicon is preferably at least substantially stable to boiling in aerated basic solutions of aqueous KOH (pH 10) and solutions of 25 % EtOH/75 % aqueous KOH (pH 10) for one hour. The corrosion rate of the derivatized porous silicon material in simulated human plasma, is a factor of at least two orders of magnitude lower than underivatized porous silicon. The porosity of the derivatized porous silicon is preferably at least 5 %. Devices comprising the derivatized porous silicon are also described. These include immunoisolation devices, biobattery devices, and optical devices.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

DERIVATIZED POROUS SILICON

This invention relates to derivatized porous silicon, to biomaterial
5 comprising derivatized porous silicon, and to applications of such
biomaterial.

A biomaterial is here defined as a non-living material used in or on the
surface of a living human or animal body. It is intended to interact with the
10 biological environment into which it is introduced. Such biomaterials can
be bio-inert, bioactive or resorbable, depending on their interaction with the
living tissue of the human or animal body. A relatively bio-inert
biomaterial, such as titanium, undergoes minimal corrosion and minimal
fibrous encapsulation by the surrounding tissue. A bioactive biomaterial,
15 such as Bioglass (RTM), undergoes corrosion and thereby encourages tissue
growth on its surface. A resorbable biomaterial, such as a polylactide,
undergoes sufficient continuous corrosion to be completely dissolved in the
body over a period of time.

20 To varying extents, the practical viability of most biomedical devices and
structures (i.e. devices and structures used in or on the surface of a living
human or animal body) will depend upon such issues as stability of their
constituent biomaterial and interactions between the biomaterial surface and
the biological environment of the body within which or on which the device
25 is placed. For some applications (e.g. reconstructive prosthetics, wound
repair, biochip integration, drug delivery) biomaterial corrosion is
desirable. The extent of the desired corrosion will depend on the specific
application, but in many it is desirable that the biomaterial is substantially
stable within its environment i.e. that corrosion takes place over a long
30 period of time. For other applications (e.g. biosensing, biofiltration, neuro-

interfacing) a stable interface between the biomaterial and its environment is needed, i.e. it is desirable that there is little or preferably no corrosion of the biomaterial. For biofiltration applications in particular, the biomaterial is also required to be porous, indeed often highly porous. The requirements
5 of stability and porosity often conflict, as a material is made more porous its stability can often decrease.

Silicon has for many years not been considered a viable biomaterial due to its perceived bioincompatibility. It has recently been shown that by
10 introducing varying levels of porosity into silicon, its biocompatibility can be increased. Porous silicon although biocompatible in some biological environments has not been found to be stable in living human or animal bodies or simulations thereof. Corrosion takes place in days or even hours. However, as stated above, there are many applications where stability or at
15 least substantial stability of a biomaterial is desired.

According to a first aspect of the present invention there is provided derivatized porous silicon for use as a biomaterial.

20 According to a second aspect of the present invention there is provided biomaterial comprising derivatized porous silicon.

According to a third aspect of the present invention there is provided a biomedical device comprising derivatized porous silicon.

25

For the absence of doubt, derivatized porous silicon is to be taken as porous silicon having a substantially monomolecular layer that is covalently bonded to at least part of its surface. The surface of the porous silicon includes the surfaces of the pores. As is well known porous silicon is
30 silicon that has been porosified, by anodisation, stain etching, or

photochemical etching in HF based solutions. Porous silicon fabricated in this way has a porosity greater than 0.1% and more typically greater than 1%.

- 5 Derivatization of the porous silicon has been found to increase its stability.

According to a fourth aspect of the present invention there is provided a biofiltration device comprising derivatized porous silicon.

- 10 The biofiltration device may be adapted for operation in or on the surface of a human or animal body. The biofiltration device may be adapted for use in vitro. The biofiltration device may comprise one or more derivatized porous silicon filters. The or each or some of the filters preferably act as molecular sieves. They preferably allow some molecules e.g. nutrients and
15 waste products to pass through them, but prevent other molecules e.g. components of the immune system such as macrophages and immunoglobulin molecules from doing so. The pore size of the or each or some of the filters preferably determines the molecules which pass through them. The diameter of the pores of the or each or some of the filters may be
20 in the range 15-50nm. The or each or some of the filters may have a thickness of a few μms . The porosity of the or each or some of the filters is preferably at least 5%, and could be 10% or 15% or higher.

- The biofiltration device may form part of a multi-element device. The
25 multi-element device may be adapted for operation in or on the surface of a human or animal body. The multi-element device may be a biosensor. The biosensor may be adapted for operation in or on the surface of a human or animal body. The biosensor may monitor one or more physiological functions of the body. The biosensor may monitor one or more aspects of
30 one or more fluids of the body. The biosensor may monitor glucose levels,

and/or lithium ion levels and/or potassium and/or alcohol levels within the body.

According to a fourth aspect of the present invention there is provided an
5 immunoisolation device comprising derivatized porous silicon.

The immunoisolation device may be adapted for operation in or on the surface of a human or animal body. The immunoisolation device may be adapted for use in vitro. The immunoisolation device may comprise a silicon capsule, of thickness preferably less than or equal to 500µm. The
10 immunoisolation device, and preferably the capsule, may be provided with one or more derivatized porous silicon filters. The derivatized porous silicon may be derivatized mesoporous silicon. The or each or some of the filters preferably exclude at least some molecules of the immune system from the device. Such molecules may be, for example, macrophages and
15 immunoglobulin molecules. The or each or some of the filters preferably allow non-immune system molecules into and out of the device. Such molecules may be, for example, nutrients and waste products. The pore size of the or each or some of the filters preferably determines the molecules which pass through them. The diameter of the pores of the or each or some
20 of the filters is preferably in the range 15-50nm. The or each or some of the filters may be produced by anodisation of one or more parts of the capsule. The or each or some of the filters may have a thickness of a few µms. The porosity of the or each or some of the filters is preferably at least 5%, and could be 10% or 15% or higher.

25

Cells may be placed within the device, to isolate them from components of the immune system, and may be cultured on the inner surfaces of the or each or some of the derivatized porous silicon filters. Such cells may be insulin-secreting cells (Islets of Langerhans), baby hamster kidney cells
30 releasing ciliary neuro-trophic factor for treatment of amyotrophic lateral

sclerosis, bovine adrenal chromaffin cells for treatment of intractable pain. In this case, the pore size of the or each or some of the filters is preferably large enough to allow nutrients for the cells to diffuse into the device and waste products and insulin to diffuse out of the device, but have a
5 distribution of size such as to exclude all cells and specific proteins of the immune system from the device.

According to a fifth aspect of the present invention there is provided a battery device comprising derivatized porous silicon.

10

The battery device may be adapted for operation in or on the surface of a human or animal body. The battery device may be adapted for use in vitro. The battery may comprise a power source. The power source may comprise one or more bioluminescent organisms which emit light. The or each or
15 some of the organisms may be micro-organisms genetically modified with green fluorescent protein (GFP). This preferably realises high quantum yields (greater than 50%) and electrical power high enough to drive CMOS transistors. The or each or some of the organisms may contain luciferase enzymes which generates 560 nm light in the presence of ATP, Mg^{2+} ,
20 oxygen and luciferin. Preferably, body fluids containing nutrients, such as glucose, provide continuous energy for the organisms. The battery device may comprise one or more photodetectors, such as p-n junctions or p-i-n junctions. These may convert the light generated by the or each or some of the organisms into electrical power. The or each or some of the
25 photodetectors may be used in conjunction with one or more mirrors, to enhance the light collection efficiency.

The power source may be an electrochemical power source. This may comprise at least one pair of electrodes. Power may be generated by
30 electron transfer to and from the electrodes. The or each pair of electrodes

may comprise dissimilar metals, e.g. aluminium and silver. Such a source preferably generates at least 0.8V. The or each pair of electrodes may be provided with an enzyme attached to one of the electrodes. The enzyme may be glucose oxidase. Preferably glucose is supplied to the battery which
5 reacts with the glucose oxidase to produce hydrogen peroxide, which in turn reacts with the other electrode resulting in a transfer of electrons between the electrodes. Such a source preferably generates at least 2V.

The battery device may comprise a silicon box. The battery device, and
10 preferably the box, may be provided with one or more derivatized porous silicon filters. The derivatized porous silicon may be derivatized mesoporous silicon. The or each or some of the filters preferably exclude substances detrimental to the power source from the battery device. Such substances may include molecules of the immune system, proteins and
15 enzymes. The or each or some of the filters preferably allow substances beneficial to the power source into the battery device. Such substances may include nutrients such as glucose and water and waste products. The or each or some of the filters preferably allow substances produced by the power source to exit the battery device. Such substances may include waste
20 products. The pore size of the or each or some of the filters preferably determines the substances which pass through them. The diameter of the pores of the or each or some of the filters is preferably in the range 15-50nm. The or each or some of the filters may be produced by anodisation of one or more parts of the battery device, preferably the silicon box. The
25 or each or some of the filters may have a thickness of a few μms . The porosity of the or each or some of the filters is preferably at least 5%, and could be 10% or 15% or higher.

The battery device may provide power to one or more devices. The devices
30 may be adapted for use in or on the surface of a human or animal body, or

in vitro. Electrical connections may be provided between the battery device and the or each device. The or each or some of the devices may be microfluidic drug delivery devices, biosensors, nerve stimulation devices, identification/tagging devices.

5

According to a sixth aspect of the present invention there is provided an optical device comprising derivatized porous silicon.

Lasers, and optics in general, are increasingly being utilised in health care
10 for both non-invasive/minimally-invasive diagnostics and therapeutic treatment. Well known examples include pulse oximetry for monitoring the level of blood oxygenation, endoscopic fluorescence imaging for cancer detection, photodynamic therapy (PDT), non-invasive spectroscopy approaches to glucose monitoring, etc. A significant issue with all optical
15 diagnostic techniques is quantification/control of the path length that the light from the source being used has travelled in vivo prior to detection. A significant issue with techniques such as PDT is the minimisation of damage to healthy tissue surrounding the cancerous site being treated. Both problems arise from the inhomogeneous, highly scattering, optical
20 properties of tissue.

The device may be adapted for operation in or on the surface of a human or animal body. The device may be adapted for use in vitro. The device may be adapted for use in conjunction with a source of light. The device
25 preferably controls the path length of the light from the source. This may be achieved by strategic placement of the device within the body.

The optical device may comprise a high, preferably greater than 95%, reflectivity structure. The optical device may comprise a multilayer mirror.
30 The multilayer mirror may consist of a stack of alternating layers of

derivatized porous silicon material having a first porosity and a first refractive index, and derivatized porous silicon material having a second porosity and a second refractive index which is higher than the first refractive index. The porosity may be inversely proportional to the refractive index. The first porosity may have a value in the region of 40%, and the second porosity may have a value in the region of 90%. The first porosity may have a value in the region of 50%, and the second porosity may have a value in the region of 71%. The layers of silicon material preferably have a thickness in the region of a quarter of the wavelength of the light incident upon them. The thickness of the layers preferably lies in the region 50-1000nm. If the light incident on the layers is in the blue region of the visible spectrum, i.e. has a wavelength of approximately 400nm, the thickness of the layers is preferably in the region of 100nm. If the light is in the near infra red spectrum, i.e. has a wavelength of approximately 2 μ m, the layer thickness is preferably in the region of 500nm. When the light incident on the mirror is in the visible or near infrared spectrums, the refractive indices of the layers preferably lie in the region 1.3-3.5. The reflectivity of the mirror is preferably high (e.g. over 95%) over a single or a range of wavelengths corresponding to the wavelength or wavelengths of the light incident thereon. This is referred to as the stop band of the mirror. The wavelength position and width of the stop band is preferably controlled by the design of the mirror stack, by such characteristics as the porosities of the silicon material used, and the number and thickness of the layers. The central wavelength of the stop band (known as the Bragg wavelength, λ_{Bragg}) is given by:

$$m \lambda_{\text{Bragg}} = 2 (d_1 n_1 + d_2 n_2)$$

where m is the order of the Bragg condition, d refers to layer thickness, n to refractive index, and subscripts 1 and 2 to the first and second refractive

indices. The refractive indices of the layers may be chosen such that the stop band of the mirror lies in the region 700-1000nm. This is the spectral range where living tissue has an 'optical window'. Very high, preferably greater than 95%, levels of reflectivity are preferably achieved.

5 Using derivatized porous silicon in such optical devices improves their stability in comparison to previously known devices, and provides a means to prolong their lifetime in vitro or in or on the surface of a living human or animal body. For example, underivatized porous silicon multilayer mirrors dissolve in a few days in simulated human plasma (SHP), whereas
10 derivatized mirrors may be stable in SHP for periods of weeks or months. When used in a body, the optical device is preferably eventually degradable in the body. It does not then have to be surgically removed once no longer needed, and problems related to permanently implanted devices are avoided.

15 The optical device is preferably at least substantially hydrophobic. This limits wetting of the device by aqueous fluids e.g. body fluids, which would otherwise penetrate the device causing corrosion thereof especially from within. Any corrosion of the hydrophobic device is then dominated by surface attack.

20

The reflectivity of the mirror may depend on the number of layers in the mirror. However, the reflectivity does not generally increase linearly with the number of layers, but saturates i.e. reaches a maximum value after a certain number of layers, e.g. ten layers, called the saturation layers.

25 Addition of further layers above this number does not significantly increase the reflectivity. The mirror may comprise a number of layers greater than the number of layers required for saturation of the reflectivity. Light incident on the mirror will interact with the saturation layers. Layers beneath these will be initially 'redundant' layers, and will not significantly
30 contribute to the reflectivity of the mirror. When corrosion of the mirror is

dominated by surface attack, as the layers thereof are corroded away the reflectivity of the mirror will at least initially not be significantly affected. This is because as a layer is removed by corrosion, a previously redundant layer becomes one of the saturation layers, maintaining the number of these
5 layers. This continues until the number of layers falls beneath the number required for saturation, the reflectivity of the mirror will then start to decrease. By making the number of the redundant layers large in comparison to the number of layers required for saturation, the maximum reflectivity may be maintained until the mirror has virtually corroded away.
10 If the rate of corrosion is known, the number of redundant layers may be chosen to ensure that the reflectivity of the mirror remains at a maximum throughout the period in which the mirror is required to operate. The duration of the mirror in vitro or in or on the surface of a living human or animal body prior to resorbtion may be tuned by the number of layers
15 therein.

The optical device may be capable of bonding to bone, in vitro or in or on the surface of a living human or animal body. This may be due to bone-bonding ability of derivatized porous silicon. When used in a living body,
20 the optical device may be placed on bone, preferably close to the skin. The optical device may be placed in a subcutaneous site. The optical device may be used with an endoscope. For invasive therapeutic applications, the optical device could form part of a larger optical cavity device or micro-optical bench.

25

According to a seventh aspect of the present invention there is provided a cardiovascular device comprising derivatized porous silicon.

The cardiovascular device may be adapted for operation in or on the surface
30 of a living human or animal body, or in vitro. The device may come into

direct and possibly prolonged contact with blood. In such a case, the derivatized porous silicon is preferably haemocompatible, and the surface thereof is preferably adapted such that clotting and/or calcification thereon are avoided. Underivatized bulk silicon is known to be thrombogenic from
5 studies of blood clotting time.

The derivatized porous silicon preferably has one or more organic groups attached to the surface thereof. The organic groups may comprise hydrophilic polymer groups e.g. polyethylene oxide, and/or hydrophobic
10 polymer groups e.g. polyurethanes. The polymer groups may contain polar phospholipid groups. Such organic groups are known to confer better haemocompatibility than silicon oxide, the normal surface component of underivatized porous silicon in physiological conditions. The organic
15 groups may also be chosen for their ability to bind substances, such as heparin, albumin, phosphorylcholine or other biological agents. The organic groups may also be chosen for their ability to promote host cell overgrowth, e.g. overgrowth of endothelial cells (the cells that line the
internal surfaces of blood vessels). The derivatized porous silicon preferably has a high surface area/volume matrix in which anti-calcification
20 agents may be embedded. Using derivatized porous silicon minimises corrosion known to be a factor in promoting calcification.

According to an eighth aspect of the present invention there is provided a microelectrode device comprising derivatized porous silicon.
25

The microelectrode device may be adapted for operation in or on the surface of a living human or animal body, or in vitro. Commercial biomedical microelectrodes often use porous coatings to improve tissue integration and thereby lower interfacial impedance. Such porous coatings however need to
30 remain conductive and have excellent corrosion resistance when under

electrical bias. Underivatized porous silicon microelectrodes would undergo significant corrosion in most physiological conditions of pH greater than 7, e.g. soft tissue, bone, muscle and blood. The application of electrical bias to the electrodes, corresponding to a positive surface charge, would accelerate this degradation. The impedance would rise with time and the ac drift would also be unacceptable. Using derivatized porous silicon in the manufacture of microelectrode devices seeks to alleviate these problems.

10 According to an ninth aspect of the present invention there is provided a wound repair device comprising derivatized porous silicon.

The wound repair device may be adapted for operation in or on the surface of a living human or animal body, or in vitro. The wound repair device may comprise derivatized porous silicon microvelcro. Such a device is porous and yet at least substantially stable in vitro and in or on the surface of a living human or animal body. The device may be impregnated, for example with one or more bioactive agents such as antibiotics and/or silver.

20 According to a tenth aspect of the present invention there is provided a radiotherapy device comprising derivatized porous silicon.

Radiotherapy is an effective treatment of cancers. Glass microspheres have been developed for in-situ irradiation. The radioactive material is embedded in the glass, which must have very low corrosion rates in body fluids to ensure that there is minimal-radiation dose to neighbouring organs. Using derivatized porous silicon for the manufacture of radiotherapy devices ensures good stability thereof in vitro or in or on the surface of a living human or animal body. Derivatized porous silicon may be micromachined into a variety of shapes, the device may be shaped to match

the shape of a physiological site to which it is intended to attach, e.g. a bone tumour.

According to an eleventh aspect of the present invention there is provided a
5 drug delivery device comprising derivatized porous silicon.

The drug delivery device may be adapted for operation in or on the surface of a living human or animal body. By using derivatized porous silicon the stability of the device is substantially improved over existing devices, and
10 the payload of the drug is preferably improved. The device may be capable of very long-term delivery (i.e. many months to years). Derivatization preferably also provides a means of covalently binding a range of therapeutic elements and/or low molecular weight drug molecules to the internal surface of the derivatized porous silicon. The improved stability of
15 the device preferably aids electrical control of drug delivery. The derivatized porous silicon may comprise one or more functional groups bonded to the surface thereof. These preferably protect the underlying silicon from corrosion. They may be eventually degradable e.g. resorbable in physiological conditions. They preferably degrade to non-toxic products.
20 They may be resorbable polymers, which may degrade into CO₂ and water after prolonged hydrolysis.

The derivatized porous silicon is preferably derivatized by a technique that does not involve oxidation of the silicon. This technique may result in
25 derivatized porous silicon having Si-R termination, where R is one or more functional groups attached to the silicon via Si-C bonds. Using such a technique has a number of advantages. The derivatized porous silicon is more stable than underivatized porous silicon. Termination of the silicon via Si-C bonds prevents oxidation of the silicon, i.e. formation of Si-O_x
30 bonds on the surface thereof. This maintains the semiconducting nature of

the material, silicon oxide being an insulator.

The porous silicon is preferably derivatized by hydrosilylation, and more preferably by Lewis acid mediated hydrosilylation. The Lewis acid may be
5 EtAlCl₂. The hydrosilylation preferably involves covalent modification of the surface of the porous silicon, preferably by hydrosilylation of alkynes and/or alkenes yielding vinyl and/or alkyl groups bound to the surface of the porous silicon.

10 Derivatization preferably improves the stability of the porous silicon under oxidising conditions. The derivatized porous silicon is preferably stable to boiling in aerated water for preferably at least two hours. Unmodified (i.e. underivatized) porous silicon undergoes substantial oxidation and degradation in boiling water after one hour. The derivatized porous silicon
15 is preferably at least substantially stable to boiling in aerated basic solutions of aqueous KOH (pH 10) and solutions of 25% EtOH/75% aqueous KOH (pH 10) for one hour. Unmodified porous silicon dissolves rapidly under these conditions.

20 Porous silicon can be subdivided according to the nature of the porosity. Microporous silicon contains pores having a diameter less than 20Å; mesoporous silicon contains pores having a diameter in the range 20Å to 500Å; and macroporous silicon contains pores having a diameter greater than 500Å. The derivatized porous silicon may be derivatized mesoporous
25 silicon.

The corrosion rate of the derivatized mesoporous silicon material in simulated human plasma is preferably a factor of at least two orders of magnitude lower than underivatized mesoporous silicon.

30 The porosity of the derivatized porous silicon is preferably at least 5% (i.e.

its void fraction or percentage of air may be 5%), but could be as high as 60% or 70%, 80% or 90%. The stability of such high porosity material demonstrates that for the first time high porosity structures can be realised that are both (a) not heavily oxidised and hence semiconducting in nature
5 and (b) relatively stable for physiological environments. In comparison, underivatized high porosity (75%) mesoporous silicon undergoes some degree of corrosion under physiological conditions of pH 7, and is resorbable in vitro and in vivo. Thin films (5-10 μ m thick) of such underivatized mesoporous silicon are found to dissolve in simulated human
10 plasma after one day.

According to a twelfth aspect, the invention provides a corrosion analysis system comprising:

- 15 (a) a source of electromagnetic radiation;
 (b) a detector of electromagnetic radiation;
 (c) a processing means;

characterised in that, when in use, the source is arranged such that it is
20 capable of irradiating at least one multi-layer porous silicon or derivatised porous silicon mirror, the detector is arranged such that it is capable of detecting radiation reflected from said at least one mirror, and the processor means is adapted such that it is capable of processing a signal generated by said detector to yield information relating to corrosion of the or each
25 mirror.

For example the source and detector may form part of a spectrometer for determining the reflectance or transmittance of the mirror or mirrors. The corrosion may result from implantation of the mirror in an animal or human
30 body.

The processor means may be adapted such that it is capable of processing a signal generated by said detector to yield the number of layers present in the or each mirror.

5

Corrosion may result in loss of the number of layers from which the mirror is formed. The processor means may be adapted to provide information relating to the number of layers that have been lost or to the number of surviving layers.

10

Alternatively the processor means may be adapted such that it is capable of processing a signal generated by said detector to yield the amount of any substance that has been eroded from the or each mirror.

15 The mirror may comprise a substance, such as a drug or a mineral. As the mirror is corroded the substance may be released into the body of the animal or human. The processor means may be adapted such that it is capable of yielding information relating to the amount of the substance that has been lost through corrosion, or information relating to the amount of the
20 substance that survives in the uncorroded part of the mirror.

The corrosion analysis system may further comprise said at least one mirror.

25 Embodiments of the invention will now be described by way of example, with reference to the accompanying drawings, in which:

Figure 1 is a schematic representation of the derivatization of
hydride terminated porous silicon through a Lewis acid
30 mediated hydrosilylation reaction of 1 dodecyne;

5 **Figures 2 (a), (b), (c) and (d)** show plan and cross sectional scanning electron microscopy (SEM) images of underivatized porous silicon (a, b) before SHP exposure, and derivatized porous silicon (c, d) after 4 weeks immersion in SHP;

10 **Figures 3 (a), (b) and (c)** show plan view SEM images of underivatized porous silicon surface after varying times in SHP (a) 1 hour, (b) 5 hours, (c) 70 hours;

15 **Figures 4 (a), (b) and (c)** show secondary ion mass spectroscopy (SIMS) depth profiles of the oxygen content of (a) derivatized porous silicon prior to SHP exposure but after 6 weeks aging i.e. storage in air, (b) underivatized porous silicon after 5 hours SHP exposure, and (c) derivatized porous silicon after 4 weeks SHP exposure;

20 **Figures 5 (a), (b) and (c)** show Fourier transform infra red spectroscopy (FTIR) spectra of (a) freshly derivatized porous silicon, (b) derivatized porous silicon after 4 weeks in SHP, and (c) derivatized porous silicon after 2 months in ambient air;

25 **Figures 6 (a) and (b)** show cross sectional and plan views of an immunoisolation device;

30 **Figure 7** shows a cross sectional schematic view of a first embodiment of a battery device;

Figure 8 shows a cross sectional schematic view of a second embodiment of a battery device;

Figure 9 shows a schematic representation of a multilayer mirror;

5

Figures 10 (a) and (b) show EDAX results for derivatised porous silicon mirrors;

Figure 11 shows the effect of incubation in SHP on an 80 layer mirror comprising dodecenyl terminated porous silicon;

10

Figure 12 shows the effect of incubation in SHP on a 40 layer mirror comprising dodecyl terminated oxidised porous silicon;

15

Figures 13 (a) and (b) show reflectivity spectra for an 80 layer mirror comprising dodeceny terminated oxidised porous silicon before and after immersion in SHP;

20

Figure 14 shows a theoretical prediction of the variation of reflectivity with the number of layers of derivatised porous silicon;

Figure 15 shows a schematic diagram of a biofiltration device according to the invention;

25

Figure 16 shows a cardiovascular device according to the invention;

Figure 17(a) shows a schematic diagram of a part of a wound repair device according to the invention;

30

Figure 17(b) shows a schematic diagram of a microelectrode device according to the invention;

5 **Figure 18(a)** shows a schematic diagram of a radiotherapy device according to the invention;

Figure 18(b) shows a part of a drug delivery device according to the invention; and

10

Figure 19 shows a corrosion analysis system according to the invention.

Figure 1 shows a schematic representation of the derivatization process on
15 silicon wafers. These are (100) p-type boron doped wafers with resistivity of 7.5-8.5 Ωcm . These were previously anodised galvanostatically at 1.7 mAcm^{-2} in a 1:1 by volume mixture of 48% HF:C₂H₅OH for 5 minutes in the dark to yield a single layer of porous silicon. This single layer of porous silicon has a substantially uniform porosity throughout its thickness.
20 Subsequent rinsing with ethanol and excess dry hexane was then carried out without permitting intermediate drying of the wafers. Derivatization was then carried out, using a Lewis acid (EtAlCl₂) mediated hydrosilylation to replace the silicon hydride termination of the wafers. Hydrosilylation was carried out with 1 dodecyne and yielded a dodecenyl terminated surface.
25 The Lewis acid mediated hydrosilylation was performed in the following manner:

A hexane solution of the Lewis acid (EtAlCl₂) is brought into contact with the surface of the freshly anodized sample of porous silicon (comprising a
30 single layer of uniform porosity). 1 dodecyne is then also placed on the

surface of the porous silicon and the consequent reaction is allowed to proceed at an ambient temperature of 20 C for a period of 1 hour. The sample is then quenched with THF, followed by CH₂Cl₂. The whole process, from the application of the Lewis acid through to the quenching with
5 CH₂Cl₂ is performed in an inert atmosphere. The derivatized sample is then rinsed in ethanol and dried under an N₂ stream.

The resulting surface is capped with a monolayer of dodecanyl groups. Such derivatized material only undergoes minor levels of oxidation even
10 after one hour in boiling basic solutions (pH 10) of aqueous KOH. To put this into context, strongly basic solutions are frequently used to selectively dissolve many μ m of porous silicon from wafers within seconds to minutes at room temperature.

15 The response of such wafers to physiological environments (pH 7.3) has been assessed. Derivatized material was exposed to SHP and its degree of corrosion, oxidation and calcification monitored by scanning electron microscopy (SEM), Fourier transform infra red spectroscopy (FTIR) and secondary ion mass spectroscopy (SIMS). These were compared with
20 control wafers of the same microstructure, which were not derivatized and thus had hydride termination.

The derivatized and control wafers were incubated at 37° for periods of hours to weeks in the acellular SHP. The ion concentration of the SHP is as
25 follows:

ION	CONCENTRATION (mM)
Na ⁺	142.0
K ⁺	5.0
Mg ²⁺	1.5

Ca^{2+}	2.5
HCO_3^-	4.2
HPO_4^{2-}	1.0
Cl^-	147.8
SO_4^{2-}	0.5

Figures 2(a) and 2(b) show the surface topography of a control wafer before SHP exposure. The porous silicon layer of the wafer is relatively thin (275±15nm at the centre of the 155mm² anodised area rising gradually to 350±15nm at its circumference), and has some nanometre surface particulate contamination indicated by arrows. Figure 3(a) reveals the rapid increase in surface roughness of the control material that occurs within one hour exposure to this simulated physiological environment. After 5 hours (Figure 3(b)) there is evidence for a combined dissolution-deposition process occurring, and by 70 hours (Figure 3(c)) large areas of the control wafer had been completely removed, with that remaining having a heavily roughened appearance.

Figures 2(c) and 2(d) show the surface topography of a derivatized wafer after 4 weeks immersion in SHP. In striking contrast, the derivatized porous silicon layer thickness is essentially unchanged. Much of the change in surface topography of Figure 2(c) compared with that of Figure 2(a) is likely to arise from very thin SHP deposits. The nanometre scale pitting corrosion arrowed appears to correlate with surface particulates present after anodisation but prior to derivatization. Assuming they locally shield small areas from dodecenyl termination, which then become undercut, this form of corrosion is not intrinsic to the derivatization process nor derivatized material.

A comparison of Figures 2 and 3, with the additional observation that after

70 hours most of the 275nm thick underivatized porous silicon layer had been completely removed, indicates the dramatic change in stability brought about by this derivatization process. From Figures 2(a) and 2(d) and Figure 4 one can estimate that any layer thinning over the approximately 4 week (700 hour) period is $\leq 25\text{nm}$ for the derivatized material, but on average approximately 250 nm over 70 hours for the underivatized control material. Consequently the corrosion rate over these time periods and under these physiological conditions has been reduced by at least a factor of 100.

10 The extent to which the derivatized porous silicon has been infiltrated by the SHP and undergone oxidation has been investigated. SIMS profiles revealed substantial levels of Na, K, Cl Mg and Ca throughout the depth of the wafer. Since these elements are present in SHP but have very low levels in both freshly etched and aged (in ambient air) porous silicon, there is little doubt that the SHP solution has infiltrated the pores of the silicon to some degree. Figures 4(a), (b) and (c) compare the oxygen levels in aged derivatized porous silicon to that of SHP treated underivatized and derivatized porous silicon. SIMS analysis was conducted towards the circumference of the anodized area for each of the three materials indicated, where cross sectional SEM images indicated an initial wafer thickness of 315 ± 15 nm. The underivatized porous silicon has a higher degree of oxidation after 5 hours in SHP (and has been noticeably thinned) than the derivatized porous silicon after 4 weeks immersion. Nonetheless, it is clear that some additional oxidation of the derivatized porous silicon has occurred in SHP as compared with derivatized porous silicon stored in air for 6 weeks.

The above is verified by FTIR analysis (Figure 5). The relative amounts of silicon back-bonded to oxygen appear similar to the ambient air aged control material, but the Si-O stretch mode around 1100 cm^{-1} in the SHP

immersed material is significantly greater. This would be consistent with the backbone of the porous silicon undergoing hydrolysis, whilst its hydrophobic surface groups protect the surface, keeping it intact. The ν (C=C) stretch diminishes in intensity after 4 weeks immersion in SHP as can be observed upon comparison of Figures 5(a) and 5(b), possibly due to isomerization of the predominantly cis form of the double bond to the more thermodynamically stable trans confirmation under these conditions. In the case of the porous silicon material stored in air for 6 weeks, adsorption of hydrocarbon impurities takes place, as indicated by the change in ratio of ν (CH₃) and ν (CH₂) at 2690 cm⁻¹ and 2925 cm⁻¹ respectively, and by the increase in the intensity of δ (CH₂) at 1460 cm⁻¹.

Figures 6 (a) and (b) show cross sectional and plan views of a immunoisolation device for containing insulin-secreting cells. This comprises a capsule of single crystal silicon wafer 1, having a reservoir 2 containing the insulin-secreting cells, a derivatized mesoporous silicon filter 3 and a lid 4 provided with a derivatized mesoporous silicon filter 5. The capsule is used in a living human or animal body, and the cells interface with the body via the filters.


The reservoir is photolithographically defined, by using an anisotropic etchant such as KOH. The capsule lid comprises a commercially available silicon membrane, and is bonded to the capsule using a very thin layer, e.g. less than 1 μ m, of medical adhesive known to be resistant to hydrolysis, such as cyanoacrylate or dental adhesive or silicone elastomer. Alternatively, a direct silicon to silicon bond or silicon to SiO_x to silicon bond can be used, formed by a process which does not raise the temperature of the capsule by more than 30°C, so as not to damage the cells. The dimension of the capsule from filter 3 to filter 5 is 500 μ m or less. This ensures that the insulin secreting cells are not more than 500 μ m from blood

vessels or other sources of nutrients, which would cause them to work poorly or even die. Thicker capsules can be realised, and have the advantage of being able to hold larger numbers of cells. However, the internal surfaces of such capsules have to be seeded with cells such as
5 endothelial cells to help support the cells placed in the capsule. The derivatized porous silicon filters 3,5 are provided by anodisation of portions of the capsule and the lid. They have thicknesses of a few μms , and porosities in excess of 5% for 50nm diameter pores and 15% for 15-30nm diameter pores. This allows sufficient nutrient levels to reach the insulin-secreting cells, and have sufficient diffusional throughput to allow rapid
10 insulin release in response to changing glucose levels in the body.

Figure 7 shows a cross sectional schematic view of a first embodiment of a battery. This comprises a substantially hollow silicon box 1 having first
15 and second derivatized mesoporous silicon filters 2,3, and first and second photodetectors 4,5. The photodetectors are manufactured from silicon and comprise p-n junctions. A bioluminescent organism containing green fluorescent protein is contained within the cavity 6 of the box. Light produced by the organism is received by the photodetectors 4,5, and
20 converted to electrical power. The filters 2,3 allow nutrients such as glucose to pass into the box and waste products to leave the box, but prevent components of the immune system, which might destroy the organism, from entering the box.

25 Figure 8 shows a cross sectional schematic view of a second embodiment of a battery. This comprises first and second layers of bulk non-porous silicon 1,2, and first and second derivatized porous silicon filters 3,4. First and second electrodes 5,6 are held between the layers of bulk silicon. The cavity 7 formed between the bulk and porous silicon contains a fluid, e.g. a
30 body fluid. The first electrode 5 comprises aluminium, and the second

electrode 6 comprises silver. Electron transfer occurs between the electrodes through the fluid, generating electrical power. This electrode system generates about 0.8V, and has a short circuit current determined by the electrode area. The electrodes are provided with electrical connections
5 (not shown), to channel the power out of the battery. The filters 2,3 prevent substances detrimental to the electrodes from coming into contact them. In a further embodiment, the first electrode 5 has glucose oxidase enzyme anchored thereto. Glucose entering the battery via the filters is catalysed by the enzyme to yield hydrogen peroxide. This takes place in the following
10 reaction at the second electrode 6:



This results in electron transfer between the electrodes generating electrical
15 power. This electrode system generates about 2V. The filters allow substances beneficial to the electrodes e.g. glucose to pass into the battery, but prevent substances detrimental to them from entering the battery.

Figure 9 is a schematic representation of a multilayer mirror. Two types of
20 multilayer mirror were fabricated: a 40 layer mirror and an 80 layer mirror. The mirrors were fabricated by anodization of 0.01Ωcm resistivity p-type silicon wafer using 20% ethanoic HF acid. The current is modulated between 0.75A, for 4.5 second intervals, and 4.55A, for 2.55 second intervals. The modulation is repeated for 40 cycles to produce the 80 layer
25 mirror, or for 20 cycles to produce the 40 layer mirror. The modulation of the current in this way results in the formation of alternate layers of high 1 and low 2 porosity porous silicon. The high porosity porous silicon layers 1 have a porosity of 71% and a thickness of 180nm; the low porosity porous silicon layers 2 have a porosity of 50% and a thickness of 90nm. The
30 thickness of the layers may be varied by varying the duration of the high

and low current intervals. The anodized wafers were native oxide passivated by storing them in ambient air for a period of two years.

The 40 and 80 layer mirrors were derivatised by two different methods. The first method is similar to that described earlier for the derivatisation of a single layer of porous silicon, namely the Lewis acid/dodecyne hydrosilylation. As with the earlier method, described in relation to figure 1, the Lewis acid (EtAlCl_2) is applied to the porous silicon surface of the mirror. The 1-dodecyne is then also applied to the surface to bring about the hydrosilylation. This method of derivatisation results in dodeceny terminated porous silicon. In contrast with the earlier method, however, the porous silicon is pre-treated with HF to remove the oxide layer that is present as a result of the 2 year passivation process.

The second method of derivatisation involves immersion of the mirror in trichlorododecylsilane for 24 hours at room temperature to yield dodecyl terminated oxidised porous silicon. In contrast with the first method, the mirror is not pretreated with HF to remove the oxide layer resulting from the passivation process. The sample is rinsed in ethanol and dried under vacuum.

Both derivatised and underivatised 40 and 80 layer mirrors were incubated in simulated human plasma (SHP) at 37 C and pH 7.3. Mirrors were removed after periods ranging from a few hours to many months and the composition analysed using a JEOL 6400F scanning electron microscope. The electron microscopy results for the underivatised mirrors showed evidence of corrosion within a few hours of incubation, and 1 day's incubation was sufficient to cause mirror disintegration upon air drying.

Derivatisation of the mirrors by either the first or second method was found

not to introduce drying induced cracking or significant porosity gradients. EDAX results shown in figure 10 demonstrate impregnation of carbon through the full depth of the mirrors, showing that the pores of the mirrors do not become blocked during the derivatisation process. Figure 10a shows
5 EDAX results for a porous silicon mirror derivatised by the second method. Figure 10b shows EDAX results for a porous silicon mirror derivatised by the first method.

Figure 11 shows the effect of incubation in SHP on an 80 layer mirror
10 comprising dodecenyl derivatised porous silicon. Figure 11a shows the mirror prior to incubation, figure 11b shows the mirror after 425 hours of incubation, and figure 11c shows the mirror after 2125 hours of incubation. After 425 hours 72 of the original 80 layers remain intact, after 2125 hours approximately 50 layers remain intact beneath the deposits of
15 hydroxyapatite. This eventual calcification has slowed down the rate of dissolution; it would take more than 6 months for the the derivatised porous silicon layers to be completely dissolved.

Figure 12 shows the effect of incubation in SHP on a 40 layer mirror
20 comprising dodecyl derivatised porous silicon. Figure 12a shows the 40 layer mirror prior to incubation, figure 12b shows the 40 layer mirror after 425 hours of incubation, and figure 12c shows the mirror after 2125 hours of incubation. After 2125 hours the topmost layer is heavily oxidised, but has not dissolved. If a linear corrosion rate is assumed, complete
25 dissolution would take approximately 10 years.

Figures 13a and 13b show reflectivity spectra for a 40 layer mirror comprising dodecenyl terminated porous silicon before and after immersion in SHP. Figure 13a shows the reflectivity before immersion and figure 13b
30 shows reflectivity after immersion for 2125 hours. These results show that

corroded structures continue to function as mirrors.

Figure 14 shows a theoretical prediction of the variation of reflectivity with the number of layers of derivatised porous silicon. The prediction shows that even if only a relatively small number of layers remain, reflectivity remains high.

Figure 15 shows a schematic diagram of a biofiltration device, generally indicated by 151, according to the invention. The device 151 includes a housing 152, a glucose sensor 153, a cavity 154, a derivatized porous silicon filter 155, and a cavity closure wall 156. The biofiltration device 151 is fabricated by etching a silicon wafer to form the cavity 154 and then porosifying the surface opposite to that of the cavity. The porous silicon is then derivatised, the sensor 153 is bonded to the closure wall 156, which is in turn bonded to the housing 152 so that the sensor is disposed in the cavity 154. Medical adhesive is used for bonding the sensor 153 to the closure wall 156 and the closure wall 156 to the housing 152.

The device 151 may be located in the blood stream or tissue of a patient. The filter 155 allows glucose molecules to pass through, while preventing blood cells and other material from reaching glucose sensor 153. The use of derivatized porous silicon is advantageous because it reduces deposition of material on the filter 155. In this way deposition on both the sensor 153 and filter 155 are minimised.

25

Figure 16 shows a schematic diagram of a cardiovascular device according to the invention. The cardiovascular device shown is a stent, generally indicated by 161, comprising a support scaffold 162 and a blood flow sensor 163. The stent may be used to support an artery wall 164, maintaining its diameter; the blood flow sensor 163 detecting the blood

30

flow rate. The sensor 163 has an outer surface comprising derivatized porous silicon. The derivatisation may be selected such that clotting and/or calcification is minimised.

- 5 The sensor 163 allows the blood flow to be monitored; if an inappropriate blood flow is detected, then drugs are administered or the patient is operated upon to correct the situation. Sensors for the monitoring of blood flow or blood pressure, comprising derivatized porous silicon, may also be used in connection with other cardiovascular devices such as catheters.

10

Figure 17a shows a schematic diagram of part of a wound repair device according to the invention. The repair device comprises microvelcro, part of which is indicated by 171, that has an array of sockets 172 and plugs 173. The plugs 173 are formed from a first silicon wafer and the sockets from a
15 second silicon wafer. The side of each silicon wafer, opposite to that of the plugs 173 or sockets 172, is attached to the tissue to be repaired. The two wafers are then drawn together so that the plugs 173 are secured in the sockets 172. The derivatization of porous silicon in this way allows the corrosion rate of the porous silicon to be controlled and reduces
20 calcification. The use of a porous material allows tissue to grow into the pores, facilitating the repair of the wound.

Figure 17b shows a schematic diagram of a microelectrode device, generally indicated by 171, according to the invention. The device includes
25 a microelectrode 174, comprising derivatized porous silicon, and electrical connections 175; it may be used to electrically stimulate a body part or to monitor electrical activity within a patient. A control system (not shown), may be located at a distance from the point of electrical stimulation because of its relative bulk, and be connected to the microelectrode 174 by the
30 electrical connections 175. The porous nature of the microelectrode 174

facilitates tissue integration thereby lowering interfacial impedance. The derivatization reduces corrosion of the porous silicon, so that the electrical properties of the electrode 174 remain relatively constant.

- 5 Figure 18a shows a schematic diagram of a radiotherapy device, generally indicated by 181, according to the invention. The radiotherapy device 181 comprises derivatized porous silicon combined with a radio isotope 182 such as ^{90}Y . The device is in the form of a pellet that may be implanted into an organ in the region of a tumour.

10

The pellets may be fabricated from a silicon on oxide wafer by a multi-step process. The first step is the formation, by lithographically etching the bulk silicon layer, of a multiplicity of silicon particles bonded to the underlying silicon oxide. The silicon particles are then porosified in an HF solution, 15 the silicon oxide layer being protected with a mask during porosification. Doping with the radioisotope 182 is achieved by immersion of the porosified particles in an aqueous solution of the isotope 182 followed by evaporation. The porous silicon, which now has the isotope 182 located within its pores 183, is annealed to drive the radioisotope 182 into the 20 skeleton 184. The anneal temperature is between 300 C and 1150 C for a period of 30s to 5h. Derivatization of the doped porous silicon is followed by removal from the oxide substrate.

The use of porous silicon allows doping of the pellet throughout its volume. 25 The presence of the radioisotope 182 within the skeleton 184 of the pellet reduces leakage of the isotope 182 to parts of the body other than those being treated. Were the pellets formed from bulk crystalline silicon, this would necessitate doping by ion implantation; a relatively expensive technique that limits the doping depth. Pellets formed from bulk silicon 30 would therefore result in an increased risk of such leakage. The use of

derivatized porous silicon means that the corrosion rate, and hence loss of the radioisotope 182, is reduced.

Figure 18b shows a schematic diagram of part of a drug delivery device, generally indicated by 185, according to the invention. The device 185 comprises a sample of derivatized porous silicon in which molecules of a pharmaceutical compound 186 are distributed in the pores 187. The porous silicon is derivatized in such a manner that the pharmaceutical is bonded to the silicon skeleton 188. Derivatization in this way potentially allows a constant rate of release for the pharmaceutical molecules 186 to be achieved.

Figure 19 shows a corrosion analysis system according to the invention, generally indicated by 191. The system 191 comprises a source of electromagnetic radiation 192, a radiation detector 193, and an optical device comprising derivatized porous silicon 195. The device 191 operates by illuminating the mirror 195. Radiation is then reflected by the mirror 195 and detected by the detector 193. The mirror is located within the body 195 of a human or animal patient. As the mirror corrodes in the body 194, its optical properties change and this change may be detected by the detector 193. In this way corrosion of the mirror 195 may be monitored in the body 194.

CLAIMS

1. Derivatized porous silicon for use as a biomaterial.
- 5 2. A biomaterial comprising derivatized porous silicon.
3. A biomedical device comprising derivatized porous silicon.
4. A biofiltration device comprising derivatized porous silicon.
- 10 5. A biofiltration device according to claim 4 which is adapted for operation in or on the surface of a human or animal body.
6. A biofiltration device according to claim 4 or claim 5 which
- 15 comprises one or more derivatized porous silicon filters.
7. A biofiltration device according to claim 6 in which the or each or some of the filters act as molecular sieves.
- 20 8. A biofiltration device according to claim 6 in which the pore size of the or each or some of the filters determines the molecules which pass through them.
9. A biofiltration device according to claim 8 in which the diameter of
- 25 the pores of the or each or some of the filters is in the range 15-50nm.
10. An immunoisolation device comprising derivatized porous silicon.
11. An immunoisolation device according to claim 10 which is adapted
- 30 for operation in or on the surface of a human or animal body.

12. An immunoisolation device according to claim 10 or claim 11 which comprises a silicon capsule.
- 5 13. An immunoisolation device according to claim 12 in which the thickness of the capsule is less than or equal to 500µm.
14. An immunoisolation device according to any of claims 10 to 13 which is provided with one or more derivatized porous silicon filters.
- 10 15. An immunoisolation device according to claim 14 in which the derivatized porous silicon is derivatized mesoporous silicon.
16. An immunoisolation device according to claim 14 or claim 15 in
15 which the or each or some of the filters exclude at least some molecules of the immune system from the device.
17. An immunoisolation device according to claim 16 in which the pore
20 size of the or each or some of the filters determines the molecules which pass through them.
18. An immunoisolation device according to claim 17 in which the
diameter of the pores of the or each or some of the filters is in the range 15-
50nm.
- 25 19. An immunoisolation device according to any of claims 14 to 18 in which the or each or some of the filters are produced by anodisation of one or more parts of the capsule.
- 30 20. An immunoisolation device according to any of claims 14 to 19 in

which the or each or some of the filters have a thickness of a few μms .

21. An immunoisolation device according to any of claims 14 to 20 in which the porosity of the or each or some of the filters is at least 5%.

5

22. An immunoisolation device according to any of claims 14 to 21 in which cells are placed within the capsule.

23. An immunoisolation device according to claim 22 in which the cells
10 are insulin-secreting cells.

24. An immunoisolation device according to claim 23 as dependent from any of claims 14 to 22 in which the pores of the or each or some of the filters are large enough to let nutrients for the cells diffuse into the device,
15 and waste products and insulin out of the device, but have a distribution of size such as to exclude all cells and specific proteins of the immune system from the device.

25. A battery device comprising derivatized porous silicon.
20

26. A battery device according to claim 25 which is adapted for operation in or on the surface of a living human or animal body.

27. A battery device according to claim 25 or claim 26 which comprises
25 a power source.

28. A battery device according to claim 27 in which the power source comprises one or more bioluminescent organisms which emit light.

30 29. A battery device according to claim 28 which comprises one or more

35

photodetectors which convert the light generated by the or each or some of the organisms into electrical power.

30. A battery device according to claim 27 in which the power source is
5 an electrochemical power source.

31. A battery device according to claim 30 in the power source comprises at least one pair of electrodes.

10 32. A battery device according to claim 31 in which the or each pair of electrodes comprises dissimilar metals.

33. A battery device according to claim 31 in which the or each pair of electrodes may be provided with an enzyme attached to one of the
15 electrodes.

34. A battery device according to any of claims 25 to 33 which comprises a silicon box.

20 35. A battery device according to any of claims 25 to 34 which is provided with one or more derivatized porous silicon filters.

36. A battery device according to claim 35 in which the or each or some of the filters exclude substances detrimental to the power source from the
25 battery device.

37. A battery device according to claim 35 or claim 36 in which the or each or some of the filters allow substances beneficial to the power source into the battery device.

30

38. A battery device according to any of claims 35 to 37 in which the or each or some of the filters allow substances produced by the power source to exit the battery device.

5 39. A battery device according to any of claims 35 to 38 in which the pore size of the or each or some of the filters determines the substances which pass through them.

40. A battery device according to claim 39 in which the diameter of the
10 pores of the or each or some of the filters is in the range 15-50nm.

41. A battery device according to any of claims 35 to 40 in which the or each or some of the filters are produced by anodisation of one or more parts of the battery.

15

42. A battery device according to any of claims 35 to 41 in which the or each or some of the filters have a thickness of a few μms .

43. A battery device according to any of claims 35 to 42 in which the
20 porosity of the or each or some of the filters is at least 5%, and could be 10% or 15% or higher.

44. An optical device comprising derivatized porous silicon.

25 45. An optical device according to claim 44 adapted for operation in or on the surface of a living human or animal body.

46. An optical device according to claim 44 or claim 45 adapted for use
30 in conjunction with a source of light, and which controls the path length of the light from the source.

47. An optical device according to any of claims 44 to 46 which comprises a multilayer mirror.

5 48. An optical device according to claim 47 in which the multilayer mirror consists of a stack of alternating layers of derivatized porous silicon material having a first porosity and a first refractive index, and derivatized porous silicon material having a second porosity and a second refractive index which is higher than the first refractive index.

10

49. An optical device according to claim 48 in which the first porosity has a value in the region of 50%, and the second porosity has a value in the region of 71%.

15 50. An optical device according to claim 48 or claim 49 in which the layers of silicon material have a thickness in the region of a quarter of the wavelength of the light incident upon them.

51. An optical device according to claim 50 in which the thickness of the
20 layers lies in the region 50-1000nm.

52. An optical device according to any of claims 46 to 51 in which the reflectivity of the mirror is greater than 95% over a single or a range of wavelengths corresponding to the wavelength or wavelengths of the light
25 incident thereon.

53. An optical device according to any of claims 46 to 52 in which the mirror is stable in SHP for periods of weeks or months.

30 54. An optical device according to any of claims 44 to 53 which is at

least substantially hydrophobic.

55. An optical device according to any of claims 44 to 54 which is capable of bonding to bone.

5

56. A cardiovascular device comprising derivatized porous silicon.

57. A cardiovascular device according to claim 56 which is adapted for operation in or on the surface of a living human or animal body.

10

58. A cardiovascular device according to claim 56 or claim 57 in which the derivatized porous silicon is haemocompatible.

59. A cardiovascular device according to any of claims 56 to 58 in which the surface of the derivatized porous silicon is adapted such that clotting and/or calcification thereon are avoided.

15

60. A cardiovascular device according to any of claims 56 to 59 in which the derivatized porous silicon has one or more organic groups attached to the surface thereof.

20

61. A cardiovascular device according to claim 60 in which the organic groups comprise hydrophilic polymer groups e.g. polyethylene oxide, and/or hydrophobic polymer groups e.g. polyurethanes.

25

62. A cardiovascular device according to any of claims 56 to 61 in which the derivatized porous silicon has a high surface area/volume matrix in which anti-calcification agents are embedded.

30 63. A microelectrode device comprising derivatized porous silicon.

64. A microelectrode device according to claim 63 adapted for operation in or on the surface of a living human or animal body.
- 5 65. A wound repair device comprising derivatized porous silicon.
66. A wound repair device according to claim 65 which is adapted for operation on or on the surface of a living human or animal body.
- 10 67. A wound repair device according to claim 65 or claim 66 which comprises derivatized porous silicon microvelcro.
68. A wound repair device according to any of claims 63 to 67 which is impregnated with one or more bioactive agents such as antibiotics and/or
15 silver.
69. A radiotherapy device comprising derivatized porous silicon.
70. A radiotherapy device according to claim 69 which is adapted for
20 operation in or on the surface of a living human or animal body.
71. A radiotherapy device according to claim 69 or claim 70 which is shaped to match the shape of a physiological site to which they are intended to attach.
25
72. A drug delivery device comprising derivatized porous silicon.
73. A drug delivery device according to claim 72 which is adapted for operation in or on the surface of a living human or animal body.

74. A drug delivery device according to claim 72 or claim 73 which is capable of drug delivery over months or years.

75. A drug delivery device according to any of claims 72 to 74 in which
5 the derivatized porous silicon comprises one or more functional groups bonded to its surface.

76. A biomaterial or a device according to any preceding claim in which the derivatized porous silicon is derivatized by a technique that does not
10 involve oxidation of the silicon.

77. A biomaterial or a device according to claim 76 in which the derivatized porous silicon has Si-R termination, where R is one or more functional groups attached to the silicon via Si-C bonds.

15

78. A biomaterial or a device according to claim 76 or claim 77 in which the porous silicon is derivatized by hydrosilylation.

79. A biomaterial or a device according to claim 78 in which the porous
20 silicon is derivatized by Lewis acid mediated hydrosilylation.

80. A biomaterial or a device according to claim 79 in which the Lewis acid is EtAlCl_2 .

25 81. A biomaterial or a device according to any of claims 78 to 80 in which the hydrosilylation involves covalent modification of the surface of the porous silicon.

82. A biomaterial or a device according to any of claims 76 to 81 in
30 which the derivatized porous silicon is stable to boiling in aerated water for

at least two hours.

83. A biomaterial or a device according any of claims 76 to 82 in which the derivatized porous silicon is at least substantially stable to boiling in
5 aerated basic solutions of aqueous KOH (pH 10) and solutions of 25% EtOH/75% aqueous KOH (pH 10) for one hour.

84. A biomaterial or a device according to any of claims 76 to 83 in which the derivatized porous silicon is derivatized mesoporous silicon.
10

85. A biomaterial or a device according to claim 84 in which the corrosion rate of the derivatized mesoporous silicon material in (SHP) is a factor of at least two orders of magnitude lower than underivatized mesoporous silicon.
15

86. A biomaterial or a device according to any of claims 76 to 85 in which the porosity of the derivatized porous silicon is at least 5%.


87. Biomaterial substantially as described herein with reference to
20 Figures 1 to 5 of the accompanying drawings.

88. An immunoisolation device substantially as described herein with reference to Figure 6 of the accompanying drawings.

25 89. A battery device substantially as described herein with reference to Figures 7 and 8 of the accompanying drawings.

90. A multilayer mirror substantially as described herein with reference to Figure 9 of the accompanying drawings.
30

Fig.1.




2/16

Fig.2a.



Fig.2b.




3/16

Fig.2c.



Fig.2d.



4/16

Fig.3a.



Fig.3b.






Fig.3c.



5/16

Fig.4.



6/16

Fig.5a.




Fig.5b.





Fig.5c.



7/16

Fig.6a.




Fig.6b.




Fig.7.




Fig.8.





Fig.9.



9/16

Fig.10a.





Fig.10b.



10/16

Fig.11a.




Fig.11b.





Fig.11c.



11/16

Fig.12a.




Fig.12b.




Fig.12c.






Fig.13a.



13/16

Fig. 13b.



14/16

Fig.14.





Fig.15.



15/16

Fig.16.




Fig.17a.




Fig.17b.




Fig.18a.




Fig.18b.





Fig.19.



INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 00/01450

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61L27/02 A61L31/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>BURIAK J M ET AL: "LEWIS ACID MEDIATED FUNCTIONALIZATION OF POROUS SILICON WITH SUBSTITUTED ALKENES AND ALKYNES" JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, US, AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC, vol. 120, February 1998 (1998-02), pages 1339-1340, XP002920673 ISSN: 0002-7863 page 1339, left-hand column, paragraph 1 - paragraph 2</p> <p style="text-align: center;">--- -/--</p>	1,76-82

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

16 August 2000

Date of mailing of the international search report

21/09/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Cousins-Van Steen, G

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 00/01450

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BANSAL, ASHISH ET AL: "Alkylation of Si Surfaces Using a Two-Step Halogenation / Grignard Route" J. AM. CHEM. SOC. (1996), 118(30), 7225-7226 , XP002145038 the whole document	1,76-82
A	A JANSHOFF ET AL: "Macroporous p-type silicon Fabry-Perot layers. Fabrication, characterization and applications in biosensing" JOURNAL OF THE AMERICAN CHEMICAL SOCIETY,US,AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC, vol. 120, no. 46, 25 November 1998 (1998-11-25), pages 12108-12116, XP002125399 ISSN: 0002-7863 abstract page 12114, right-hand column, paragraph 3	1-3
A	WO 97 06101 A (CANHAM TREVOR LEIGH ;SECR DEFENCE (GB)) 20 February 1997 (1997-02-20)	
X,P	CANHAM, LEIGH T. ET AL: "Derivatized mesoporous silicon with dramatically improved stability in simulated human blood plasma" ADV. MATER. (WEINHEIM, GER.) (1999), 11(18), 1505-1507 , 17 December 1999 (1999-12-17), XP000902381 page 1505, left-hand column, paragraph 2 -right-hand column, paragraph 1 page 1506, right-hand column, paragraph 2	1-9, 76-87
X,P	BURIAK, JILLIAN M.: "Organometallic chemistry on silicon surfaces: formation of functional monolayers bound through Si-C bonds" CHEM. COMMUN. (CAMBRIDGE) (1999), (12), 1051-1060 , 1 June 1999 (1999-06-01), XP002145037 the whole document	1-3
X,P	BOUKHERROUB, R. ET AL: "New Synthetic Routes to Alkyl Monolayers on the Si(111) Surface" LANGMUIR (1999), 15(11), 3831-3835 , 21 June 1999 (1999-06-21), XP000925257 the whole document	1

-/--

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 00/01450

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	<p>DANCIL, KEIKI-PUA S. E.A: "A Porous Silicon Optical Biosensor : Detection of"</p> <p>J. AM. CHEM. SOC.,</p> <p>vol. 121, no. 34,</p> <p>1 September 1999 (1999-09-01), pages 7925-7930, XP002145036</p> <p>the whole document</p> <p style="text-align: center;">-----</p>	1-3

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PC1/GB 00/01450

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9706101 A	20-02-1997	GB 2303847 A	05-03-1997
		AU 6626496 A	05-03-1997
		CA 2228426 A	20-02-1997
		EP 0842113 A	20-05-1998
		GB 2317885 A,B	08-04-1998
		GB 2337255 A,B	17-11-1999
		JP 11510469 T	14-09-1999